Table 1 Pharmacological interventions investigated in randomized clinical trials for preventing clotting during continuous renal replacement therapy.
From: How to Prolong Filter Life During Continuous Renal Replacement Therapy?
Intervention | Number of trials | Total number of participants in the trials |
|---|---|---|
Anticoagulants | ||
Regional citrate anticoagulation | 14 | 1697 |
Systemic heparin infusion | 24 | 1837 |
Low molecular weight heparin | 11 | 584 |
Regional heparin with protamine reversal | 6 | 441 |
Nafamostat mesylate | 2 | 133 |
Direct thrombin inhibitors (hirudin and bivalirudin) | 3 | 53 |
Antiplatelet agents | ||
Prostaglandin I2 inhibitors (epoprostenol and iloprost) | 5 | 154 |
Prostaglandin E1 inhibitors (Alprostadil) | 1 | 54 |
Glycoprotein IIb/IIIa antagonists (tirofiban) | 1 | 40 |
Placebo or no pharmacological intervention | 3 | 177 |